Patents by Inventor Shaokun Shu

Shaokun Shu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mechanism of resistance to bet bromodomain inhibitors
    Patent number: 11666580
    Abstract: The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 6, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kornelia Polyak, Shaokun Shu, James E. Bradner, Charles Yang Lin
  • MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS
    Publication number: 20200368248
    Abstract: The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 26, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Kornelia Polyak, Shaokun Shu, James E. Bradner, Charles Yang Lin